

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Ki-67 (D3B5) Rabbit Antibody (Alexa Fluor 488 Conjugate)

RRID:AB_2687824

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 11882, RRID:AB_2687824

Antibody Information

URL: http://antibodyregistry.org/AB_2687824

Proper Citation: Cell Signaling Technology Cat# 11882, RRID:AB_2687824

Target Antigen: Ki-67 (D3B5)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IF-F, IF-IC, F

Antibody Name: Ki-67 (D3B5) Rabbit Antibody (Alexa Fluor 488 Conjugate)

Description: This monoclonal targets Ki-67 (D3B5)

Target Organism: rat, mouse, human

Antibody ID: AB_2687824

Vendor: Cell Signaling Technology

Catalog Number: 11882

Record Creation Time: 20231110T034040+0000

Record Last Update: 20260829T095356+0000

Ratings and Alerts

No rating or validation information has been found for Ki-67 (D3B5) Rabbit Antibody (Alexa Fluor 488 Conjugate).

No alerts have been found for Ki-67 (D3B5) Rabbit Antibody (Alexa Fluor 488 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhao Y, et al. (2026) Complex II inhibitor-loaded hollow piezoelectric nanocarriers potentiate respiration-driven piezocatalytic therapy for malignant pleural effusion. *Journal of controlled release : official journal of the Controlled Release Society*, 397, 115180.

Zhao Y, et al. (2026) Physiological respiration pressure-driven piezocatalytic therapy for malignant ascites with a gold-core magnified mesoporous piezoelectric nanoplatfrom. *Biomaterials*, 333, 124233.

Makhmut A, et al. (2026) Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets. *Molecular systems biology*, 22(1), 7.

Zhao Y, et al. (2026) Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(10), e13711.

Vaubel RA, et al. (2025) Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3771.

Katsushima K, et al. (2024) A therapeutically targetable positive feedback loop between Inc-HLX-2-7, HLX, and MYC that promotes group 3 medulloblastoma. *Cell reports*, 43(3), 113938.

Cutrona MB, et al. (2024) Pancreatic cancer organoid-screening captures personalized sensitivity and chemoresistance suppression upon cytochrome P450 3A5-targeted inhibition. *iScience*, 27(7), 110289.

Launonen IM, et al. (2024) Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. *Cancer cell*, 42(12), 2045.

Kader T, et al. (2024) Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma. *Cancer discovery*.

Pörtl L, et al. (2023) Microbiota-derived genotoxin tilimycin generates colonic stem cell mutations. *Cell reports*, 42(3), 112199.

Lin JR, et al. (2023) Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. *Cell*, 186(2), 363.

Yang JF, et al. (2023) Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8⁺ T cell metabolic fitness and function in tumors. *Science immunology*, 8(87), eabq2424.

Hua Y, et al. (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1⁺ T lymphocyte niches through a feed-forward loop. *Cancer cell*, 40(12), 1600.

Hillege MMG, et al. (2022) Lack of Tgfr1 and Acvr1b synergistically stimulates myofibre hypertrophy and accelerates muscle regeneration. *eLife*, 11.

Pascal LE, et al. (2021) Prostate-Specific Deletion of Cdh1 Induces Murine Prostatic Inflammation and Bladder Overactivity. *Endocrinology*, 162(1).

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Cao M, et al. (2021) Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through α -adrenergic-activated CXCL5-CXCR2-Erk signaling cascades. *International journal of cancer*, 149(2), 460.

Ringel AE, et al. (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. *Cell*, 183(7), 1848.

Liang J, et al. (2019) Inhibition of polycomb repressor complex 2 ameliorates neointimal hyperplasia by suppressing trimethylation of H3K27 in vascular smooth muscle cells. *British journal of pharmacology*, 176(17), 3206.

Malcov-Brog H, et al. (2018) UV-Protection Timer Controls Linkage between Stress and Pigmentation Skin Protection Systems. *Molecular cell*, 72(3), 444.